Tag: Ozempic
Feb 25, 2026 | 5 minutes read | Insight Flash
REDEFINE-4 in Context: Widening Gap between NVO and LLY in Obesity Market
Novo Nordisk (NVO) shares declined following results from the REDEFINE-4 trial, where CagriSema achieved 23.0% weight loss at 84 weeks versus 25.5% f...
Learn More
Dec 1, 2025 | 5 minutes read | News
Ozempic is changing how we spend money and time, plus what we eat
...
Learn More
Nov 14, 2024 | 5 minutes read | All Posts
Mounjaro GLP1 leader in 2024
As supply constraints ease, Mounjaro is emerging as the GLP1 leader. Though our analysis of patient persistence and switches suggest a differentiated...
Learn More
Sep 10, 2024 | 5 minutes read | All Posts
GLP-1s powering Hims & Hers Health, Ro sales growth in 2024
Weight loss sales by direct-to-consumer telehealth firms Hims & Hers Health and Ro grew 112% and 213% since their respective launch months, according...
Learn More
Jul 22, 2024 | 5 minutes read | All Posts
Significant number of ex-Mounjaro patients switch to Ozempic
Earnest Analytics partnered with the BMO Capital Markets’ BioPharma team to add insight into GLP1 therapeutic usage....
Learn More
Jul 16, 2024 | 5 minutes read | All Posts
Barriers to GLP1 access drive higher telehealth use by patients living with obesity
Contact Sales for more....
Learn More
Feb 16, 2024 | 5 minutes read | All Posts
GLP-1 Series Part 4: End of Mounjaro’s bridge program drove improved gross-to-net
Contact sales for details....
Learn More
Feb 16, 2024 | 5 minutes read | All Posts
GLP-1 Series Part 3: Mounjaro driving largest declines in insulin usage
Contact sales for details....
Learn More
Feb 16, 2024 | 5 minutes read | All Posts
GLP-1 Series Part 2: Mounjaro persistence beats Ozempic in type II diabetes
Contact sales for details....
Learn More
Feb 16, 2024 | 5 minutes read | All Posts
GLP-1 Series Part 1: Utilization drives decline in DPP-4 inhibitors, increase in SGLT2s among competitive drug classes
Contact sales for details....
Learn More
Oct 25, 2023 | 5 minutes read | All Posts
High customer concentration among QSR brands suggest outsized Ozempic impact
Contact Sales for more details....
Learn More
Mar 28, 2023 | 5 minutes read | All Posts
Wegovy is Back on Shelves, Picking up Ozempic's Momentum in Obesity
...
Learn MoreSubscribe
Stay Ahead of the Curve: Join Our Global Community and Get Access to Exclusive Consumer Market Insights, Industry Ranking Reports, Product News, and Market Updates from the Consumer Edge Insight Center